Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma
Open Access
- 1 November 1999
- Vol. 86 (9) , 1832-1839
- https://doi.org/10.1002/(sici)1097-0142(19991101)86:9<1832::aid-cncr27>3.0.co;2-a
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative studyJournal of the Neurological Sciences, 1998
- Bad Is a BH3 Domain-Containing Protein That Forms an Inactivating Dimer with Bcl-XLMolecular and Cellular Biology, 1997
- The antisense bcl-2 – IgH transcript is an optimal target for synthetic oligonucleotidesProceedings of the National Academy of Sciences, 1997
- Structural and Functional Complementation of an Inactive Bcl-2 Mutant by Bax TruncationPublished by Elsevier ,1997
- Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2Nature, 1997
- Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomasEuropean Journal Of Cancer, 1996
- The p53-Binding Protein 53BP2 Also Interacts with Bcl2 and Impedes Cell Cycle Progression at G2/MMolecular and Cellular Biology, 1996
- Modulation of p53-Mediated Transcriptional Repression and Apoptosis by the Adenovirus E1B 19K ProteinMolecular and Cellular Biology, 1995
- BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with BaxNature, 1994
- Oligodendroglioma. Histologic Evaluation and PrognosisJournal of Neuropathology and Experimental Neurology, 1986